DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Bardia A, Vahdat L, Diamond J. et al.
Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥ 3-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results.
Cancer Res 2018;
78: GS1-07-GS01-07
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.